3883-58-7

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 48, p. 1362, 1983 DOI: 10.1021/jo00156a046

InChI:InChI=1/C7H10O2/c1-7(2)5(8)3-4-6(7)9/h3-4H2,1-2H3

Upstream product

• 765-69-5 2-Methylcyclopentane-1,3-dione 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 676-88-0 dimethyl(methylthio)sulfonium tetrafluoroborate 
• 3142-58-3 3,3-dimethyl-2,4-pentanedione 
• 767-55-5 2,2,5,5-tetramethyl-1,3-dioxane 
• 17082-61-0 1,2-bis(trimethylsiloxy)cyclobutene 
• 57613-21-5 3,3-Dimethyl-2,4-dioxo-cyclopentanecarboxylic acid ethyl ester 
• 77-76-9 2,2-dimethoxy-propane 
• 67-64-1 acetone 
• 5870-63-3 3-hydroxy-2-methyl-2-cyclopenten-1-one 
• 2916-31-6 2,2-dimethyl-1,3-dioxolane 
• 86439-24-9 Diethyl 2,2-dimethyl-3-oxohexanedioate 
• 695-30-7 2,2-dimethyl-1,3-dioxane 

Downstream Products

• 54857-48-6 ethyl 5-methyl-4-oxohexanoate 
• 266341-08-6 2,2-dimethyl-4,5-epoxy-cyclopentan-1,3-dione 
• 210230-86-7 8-isopropyl-2,3,6,7-tetrahydro-1,4-diazocin-5(4H)-one 

Relevant academic research and scientific papers

Synthesis of 2,2-dimethyl-4-cyclopentene-1,3-dione and 5,5-dimethyl-4-hydroxy-2-cyclopenten-1-one

Enedione 1 and related rac- and optically active enones 2 bearing a hydroxyl- 2a or a protected- 2b-c or an activated - 2d 4-hydroxyl group at C-4 have been efficiently synthesized from cheap and readily available starting materials.

SYNTHESIS OF 2,2-DISUBSTITUTED 4,9-DIHYDROXY-1H-BENZ(f)INDENE-1,3(2H)DIONES. A MODEL SEQUENCE FOR THE SYNTHESIS OF FREDERICAMYCIN

Benzindenedione 3 was prepared as a model for fredericamycin.

Stereoselective synthesis of two potential metabolites of cis-metconazole

The stereoselective synthesis of compounds 5 and 6, potential hydroxylated metabolites of the agricultural fungicide cis-metconazole, is reported. In a key step of the initially surveyed synthetic route, hydrodechlorination of 12 was competitive with hydr

Selective Derivatization of N-Terminal Cysteines Using Cyclopentenediones

The outcome of the Michael-type reaction between thiols and 2,2-disubstituted cyclopentenediones varies depending on the thiol. Stable compounds with two fused rings were formed upon reaction with 1,2-aminothiols (such as N-terminal cysteines in peptides). Other thiols gave reversibly Michael-type adducts that were in equilibrium with the starting materials. This differential reactivity allows differently placed cysteines to be distinguished and has been exploited to prepare bioconjugates incorporating two or three different moieties.

A short, protecting group-free total synthesis of bruceollines D, E, and J

A short, protecting group-free total synthesis of bruceollines D, E, and J has been achieved. The enantioselective reduction of bruceolline E with β-chlorodiisopinocampheylborane delivers both the natural and unnatural enantiomers of bruceolline J in excellent yields and enantioselectivities. Reduction with baker's yeast and sucrose was shown to provide the unnatural enantiomer of bruceolline J in 98% ee.

Methods of treating soft tissue defects

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Regio- and Stereoselective Syntheses of 7-Oxabicyclo[2.2.1]heptanes via a Gold(I)-Catalyzed Cycloisomerization of Alkynediols: Asymmetric Total Synthesis of Farnesiferol C

A highly regio- and stereoselective method to construct a broad range of 7-oxabicyclo[2.2.1]heptanes, which proceeds through a sequential reaction involving gold(I)-catalyzed cycloisomerization of alkynediols and sequential semi-pinacol-type 1,2-alkyl migration, was developed. The developed chemistry was applied to the asymmetric total synthesis of the natural product farnesiferol C.

Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors

A new class of Janus kinase (JAK) inhibitors was discovered using a rationally designed pyrrolo[1,2-b]pyridazine-3-carboxamide scaffold. Preliminary studies identified (R)-(2,2-dimethylcyclopentyl)amine as a preferred C4 substituent on the pyrrolopyridazi

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Treatment of inflammatory bowel disease

Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.